60,769 XNAS Volume
XNAS 19 Mar, 2025 3:12 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Robert C. Gray | Director | Purchase of securities on an exchange or from another person at price $ 2.94 per share. | 31 Dec 2024 | 3,500 | 11,155 (0%) | 0% | 2.9 | 10,290 | Common Stock |
| Francis Duhay | Director | Purchase of securities on an exchange or from another person at price $ 3.07 per share. | 31 Dec 2024 | 81,433 | 102,344 (0%) | 0% | 3.1 | 249,999 | Common Stock |
| Sanjay Shrivastava | Director | Purchase of securities on an exchange or from another person at price $ 2.90 per share. | 24 Dec 2024 | 5,400 | 9,288 (0%) | 0% | 2.9 | 15,660 | Common Stock |
| Robert Berman A. | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 2.55 per share. | 19 Dec 2024 | 12,000 | 222,236 (1%) | 0% | 2.6 | 30,600 | Common Stock |
| Matthew Jenusaitis M. | Director | Purchase of securities on an exchange or from another person at price $ 2.53 per share. | 19 Dec 2024 | 9,620 | 16,545 (0%) | 0% | 2.5 | 24,339 | Common Stock |
| Gray Robert C. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2024 | 19,752 | 19,752 | - | - | Stock Options | |
| Marc H. Glickman | SVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2024 | 75,000 | 75,000 | - | - | Stock Options | |
| Duhay Francis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2024 | 19,752 | 19,752 | - | - | Stock Options | |
| Shrivastava Sanjay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2024 | 19,752 | 19,752 | - | - | Stock Options | |
| M. Jenusaitis Matthew | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2024 | 19,752 | 19,752 | - | - | Stock Options | |
| Alavi Hamed | Chief Technology Officer | 18 Dec 2024 | 75,000 | 75,000 | - | - | Stock Options | ||
| Robert Berman A. | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2024 | 200,000 | 200,000 | - | - | Stock Options | |
| Hamed Alavi | Chief Technology Officer | 13 Mar 2024 | 8,334 | 91,666 | - | - | Stock Options | ||
| Hamed Alavi | Chief Technology Officer | 13 Mar 2024 | 8,334 | 8,334 (0%) | 0% | 3.6 | 29,919 | Common Stock | |
| Hamed Alavi | Chief Technology Officer | 13 Mar 2024 | 8,334 | 0 (0%) | 0% | 6.2 | 51,837 | Common Stock | |
| Robert Berman A. | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2023 | 300,000 | 300,000 | - | - | Stock Options | |
| Hamed Alavi | Chief Technology Officer | 05 Dec 2023 | 100,000 | 100,000 | - | - | Stock Options | ||
| Duhay Francis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2023 | 13,856 | 13,856 | - | - | Stock Options | |
| Craig Glynn | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2023 | 75,000 | 75,000 | - | - | Stock Options | |
| Matthew Jenusaitis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2023 | 13,856 | 13,856 | - | - | Stock Options | |
| Marc Glickman H. | SVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2023 | 100,000 | 100,000 | - | - | Stock Options | |
| Sanjay Shrivastava | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2023 | 13,856 | 13,856 | - | - | Stock Options | |
| Robert Gray C. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2023 | 13,856 | 13,856 | - | - | Stock Options | |
| Matthew Jenusaitis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2022 | 8,403 | 8,403 | - | - | Stock Options | |
| Francis Duhay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2022 | 8,403 | 8,403 | - | - | Stock Options | |
| Sanjay Shrivastava | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2022 | 8,403 | 8,403 | - | - | Stock Options | |
| Robert C. Gray | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2022 | 8,403 | 8,403 | - | - | Stock Options | |
| Robert C. Gray | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Sep 2022 | 1,041 | 7,655 (0%) | 0% | - | Common Stock | |
| Matthew Jenusaitis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Sep 2022 | 1,041 | 0 | - | - | Restricted Stock Units | |
| Matthew Jenusaitis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Sep 2022 | 1,041 | 6,925 (0%) | 0% | - | Common Stock | |
| Robert C. Gray | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Sep 2022 | 1,041 | 0 | - | - | Restricted Stock Units | |
| Francis Duhay | Director | Purchase of securities on an exchange or from another person at price $ 6.14 per share. | 16 Aug 2022 | 7,751 | 20,911 (0%) | 0% | 6.1 | 47,591 | Common Stock |
| Sanjay Shrivastava | Director | Purchase of securities on an exchange or from another person at price $ 3.85 per share. | 30 Jun 2022 | 1,000 | 3,888 (0%) | 0% | 3.9 | 3,850 | Common Stock |
| Robert A. Berman | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 3.80 per share. | 27 Jun 2022 | 2,500 | 210,236 (1%) | 0% | 3.8 | 9,500 | Common Stock |
| Craig Glynn | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2021 | 50,000 | 50,000 (0%) | 0% | - | Common Stock | |
| Craig Glynn | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2021 | 125,925 | 125,925 | - | - | Stock Options | |
| Robert C. Gray | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2021 | 7,211 | 7,211 | - | - | Stock Options | |
| Sanjay Shrivastava | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2021 | 7,211 | 7,211 | - | - | Stock Options | |
| Francis Duhay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2021 | 7,211 | 7,211 | - | - | Stock Options | |
| Marc H. Glickman | SVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2021 | 100,000 | 101,600 (0%) | 0% | - | Common Stock | |
| Marc H. Glickman | SVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2021 | 265,700 | 265,700 | - | - | Stock Options | |
| Robert A. Berman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2021 | 349,781 | 349,781 | - | - | Stock Options | |
| Robert A. Berman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2021 | 200,000 | 207,736 (1%) | 1% | - | Common Stock | |
| Matthew Jenusaitis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2021 | 7,211 | 7,211 | - | - | Stock Options | |
| Robert A. Berman | Director, CEO | Purchase of securities on an exchange or from another person at price $ 7.43 per share. | 19 Nov 2021 | 2,000 | 7,736 (0%) | 0% | 7.4 | 14,860 | Common Stock |
| Robert A. Berman | CEO | Purchase of securities on an exchange or from another person at price $ 7.87 per share. | 16 Nov 2021 | 2,000 | 5,736 (0%) | 0% | 7.9 | 15,740 | Common Stock |
| Sanjay Shrivastava | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2021 | 388 | 0 | - | - | Restricted Stock Units | |
| Sanjay Shrivastava | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2021 | 388 | 2,888 (0%) | 0% | - | Common Stock | |
| Robert C. Gray | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Sep 2021 | 1,042 | 2,084 | - | - | Restricted Stock Units | |
| Matthew Jenusaitis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Sep 2021 | 1,042 | 2,084 | - | - | Restricted Stock Units | |
| Matthew Jenusaitis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Sep 2021 | 1,042 | 5,884 (0%) | 0% | - | Common Stock | |
| Robert C. Gray | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Sep 2021 | 1,042 | 6,614 (0%) | 0% | - | Common Stock | |
| Matthew Jenusaitis | Director | Purchase of securities on an exchange or from another person at price $ 7.70 per share. | 25 Aug 2021 | 1,300 | 4,842 (0%) | 0% | 7.7 | 10,010 | Common Stock, $$0.00001 par value |
| Robert C. Gray | Director | Purchase of securities on an exchange or from another person at price $ 6.25 per share. | 16 Jun 2021 | 2,000 | 5,572 (0%) | 0% | 6.3 | 12,500 | Common Stock |
| Marc H. Glickman | SVP & Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 5.90 per share. | 21 May 2021 | 1,600 | 1,600 (0%) | 0% | 5.9 | 9,440 | Common Stock |
| Robert A. Berman | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 5.47 per share. | 18 May 2021 | 3,000 | 3,736 (0%) | 0% | 5.5 | 16,410 | Common Stock, $0.00001 par value |
| Francis Duhay | Director | Purchase of securities on an exchange or from another person at price $ 5.33 per share. | 17 May 2021 | 9,492 | 13,160 (0%) | 0% | 5.3 | 50,592 | Common Stock, $$0.00001 par value |
| Robert C. Gray | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 5,673 | 5,673 | - | - | Stock Option | |
| Sanjay Shrivastava | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 5,673 | 5,673 | - | - | Stock Option | |
| Francis Duhay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 5,673 | 5,673 | - | - | Stock Option | |
| Marc H. Glickman | SVP & CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 406,000 | 406,000 | - | - | Stock Option | |
| Robert A. Berman | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 838,000 | 838,000 | - | - | Stock Option | |
| Matthew Jenusaitis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 5,673 | 5,673 | - | - | Stock Option | |
| Robert A. Berman | CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2020 | 1,080,207 | 1,080,207 | - | - | Stock Option | |
| Robert A. Berman | CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2020 | 1,000,000 | 1,000,000 | - | - | Stock Option | |
| Robert A. Berman | CEO | Other type of transaction at price $ 0.00 per share. | 18 Jul 2020 | 1,080,207 | 0 | - | - | Stock Option | |
| Marc H. Glickman | SVP & CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2020 | 1,000,000 | 1,000,000 | - | - | Stock Option | |
| Francis Duhay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2020 | 62,500 | 107,228 (0%) | 0% | 0 | Common Stock | |
| Sanjay Shrivastava | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2020 | 62,500 | 97,500 (0%) | 0% | 0 | Common Stock | |
| Sanjay Shrivastava | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2020 | 100,000 | 100,000 | - | - | Stock Option | |
| Robert C. Gray | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2020 | 62,500 | 78,250 (0%) | 0% | 0 | Common Stock | |
| Robert C. Gray | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2020 | 100,000 | 100,000 | - | - | Stock Option | |
| Francis Duhay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2020 | 100,000 | 100,000 | - | - | Stock Option | |
| Sanjay Shrivastava | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Nov 2019 | 29,183 | 29,183 | - | - | Restricted Stock Units | |
| Sanjay Shrivastava | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Nov 2019 | 60,000 | 60,000 | - | - | Stock Options | |
| Matthew Jenusaitis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Sep 2019 | 62,500 | 62,500 (0%) | 0% | 0 | Common Stock | |
| Matthew Jenusaitis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Sep 2019 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Matthew Jenusaitis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Sep 2019 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Matthew Jenusaitis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Sep 2019 | 78,125 | 78,125 | - | - | Restricted Stock Units | |
| Robert C. Gray | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Sep 2019 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Robert C. Gray | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Sep 2019 | 78,125 | 78,125 | - | - | Restricted Stock Units | |
| Marc H. Glickman | CMO and Senior Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2019 | 180,000 | 180,000 | - | - | Stock Option (Right to Buy) | |
| Marc H. Glickman | CMO and Senior Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2019 | 184,500 | 184,500 | - | - | Stock Option (Right to Buy) | |
| Marc H. Glickman | CMO and Senior Vice President | Sale or transfer of securities back to the company at price $ 0.00 per share. | 26 Jul 2019 | 184,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Robert A. Berman | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 1.36 per share. | 12 Mar 2019 | 18,382 | 18,382 (0%) | 0% | 1.4 | 25,000 | Common Stock |
| Benedict Broennimann | Chief Medical Officer, OUS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Nov 2018 | 3,334 | 437,778 (0%) | 0% | 0 | Restricted Common Stock | |
| Marcus W. Robins | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Nov 2018 | 60,000 | 60,000 | - | - | Stock Options | |
| Marcus W. Robins | None | Grant, award, or other acquisition of securities at price $ 2.57 per share. | 27 Nov 2018 | 29,183 | 29,183 (0%) | 0% | 2.6 | 75,000 | Restricted Stock units |
| Sanjay Shrivastava | None | Grant, award, or other acquisition of securities at price $ 2.57 per share. | 27 Nov 2018 | 29,183 | 29,183 (0%) | 0% | 2.6 | 75,000 | Restricted Stock units |
| Sanjay Shrivastava | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Nov 2018 | 60,000 | 60,000 | - | - | Stock Options | |
| Francis Duhay | None | Grant, award, or other acquisition of securities at price $ 2.57 per share. | 27 Nov 2018 | 29,183 | 29,183 (0%) | 0% | 2.6 | 75,000 | Restricted Stock units |
| Francis Duhay | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Nov 2018 | 60,000 | 60,000 | - | - | Stock Options | |
| Robert A. Berman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Sep 2018 | 1,080,207 | 1,080,207 | - | - | Stock Option (Right to Buy) |